|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mikami S, Katsube K, Oya M, Ishida M,
Kosaka T, Mizuno R, Mochizuki S, Ikeda T, Mukai M and Okada Y:
Increased RANKL expression is related to tumour migration and
metastasis of renal cell carcinomas. J Pathol. 218:530–539. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jones DH, Nakashima T, Sanchez OH,
Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R,
Hojilla CV, et al: Regulation of cancer cell migration and bone
metastasis by RANKL. Nature. 440:692–696. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen LM, Kuo CH, Lai TY, Lin YM, Su CC,
Hsu HH, Tsai FJ, Tsai CH, Huang CY and Tang CH: RANKL increases
migration of human lung cancer cells through intercellular adhesion
molecule-1 up-regulation. J Cell Biochem. 112:933–941. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rao S, Cronin SJF, Sigl V and Penninger
JM: RANKL and RANK: From mammalian physiology to cancer treatment.
Trends Cell Biol. 28:213–223. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tan W, Zhang W, Strasner A, Grivennikov S,
Cheng JQ, Hoffman RM and Karin M: Tumour-infiltrating regulatory T
cells stimulate mammary cancer metastasis through RANKL-RANK
signalling. Nature. 470:548–553. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang X, Song Y, Song N, Zhang Y, Zhang L,
Wang Y, Wang Z, Qu X and Liu Y: RANKL/RANK pathway abrogates
cetuximab sensitivity in gastric cancer cells via activation of
EGFR and c-Src. Onco Targets Ther. 10:73–83. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Choi HS, Ha SY, Kim HM, Ahn SM, Kang MS,
Kim KM, Choi MG, Lee JH, Sohn TS, Bae JM, et al: The prognostic
effects of tumor infiltrating regulatory T cells and myeloid
derived suppressor cells assessed by multicolor flow cytometry in
gastric cancer patients. Oncotarget. 7:7940–7951. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mao F, Kong H, Zhao YL, Peng LS, Chen W,
Zhang JY, Cheng P, Wang TT, Lv YP, Teng YS, et al: Increased
tumor-infiltrating CD45RA-CCR7-regulatory T-cell subset with
immunosuppressive properties foster gastric cancer progress. Cell
Death Dis. 8:e30022017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lingwood D and Simons K: Lipid rafts as a
membrane-organizing principle. Science. 327:46–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Babina IS, McSherry EA, Donatello S, Hill
AD and Hopkins AM: A novel mechanism of regulating breast cancer
cell migration via palmitoylation-dependent alterations in the
lipid raft affiliation of CD44. Breast Cancer Res. 16:R192014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin BJ, Tsao SH, Chen A, Hu SK, Chao L and
Chao PG: Lipid rafts sense and direct electric field-induced
migration. Proc Natl Acad Sci USA. 114:8568–8573. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang R, Bi J, Ampah KK, Ba X, Liu W and
Zeng X: Lipid rafts control human melanoma cell migration by
regulating focal adhesion disassembly. Biochim Biophys Acta.
1833:3195–3205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Donatello S, Babina IS, Hazelwood LD, Hill
AD, Nabi IR and Hopkins AM: Lipid raft association restricts
CD44-ezrin interaction and promotion of breast cancer cell
migration. Am J Pathol. 181:2172–2187. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ha H, Kwak HB, Lee SK, Na DS, Rudd CE, Lee
ZH and Kim HH: Membrane rafts play a crucial role in receptor
activator of nuclear factor kappaB signaling and osteoclast
function. J Biol Chem. 278:18573–18580. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Parton RG and Simons K: The multiple faces
of caveolae. Nat Rev Mol Cell Biol. 8:185–194. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Salem AF, Bonuccelli G, Bevilacqua G,
Arafat H, Pestell RG, Sotgia F and Lisanti MP: Caveolin-1 promotes
pancreatic cancer cell differentiation and restores membranous
E-cadherin via suppression of the epithelial-mesenchymal
transition. Cell Cycle. 10:3692–3700. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nimri L, Barak H, Graeve L and Schwartz B:
Restoration of caveolin-1 expression suppresses growth,
membrane-type-4 metalloproteinase expression and
metastasis-associated activities in colon cancer cells. Mol
Carcinog. 52:859–870. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li L, Ren C, Yang G, Goltsov AA, Tabata K
and Thompson TC: Caveolin-1 promotes autoregulatory, Akt-mediated
induction of cancer-promoting growth factors in prostate cancer
cells. Mol Cancer Res. 7:1781–1791. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fecchi K, Travaglione S, Spadaro F,
Quattrini A, Parolini I, Piccaro G, Raggi C, Fabbri A, Felicetti F,
Caré A, et al: Human melanoma cells express FGFR/Src/Rho signaling
that entails an adhesion-independent caveolin-1 membrane
association. Int J Cancer. 130:1273–1283. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Joo HJ, Oh DK, Kim YS, Lee KB and Kim SJ:
Increased expression of caveolin-1 and microvessel density
correlates with metastasis and poor prognosis in clear cell renal
cell carcinoma. BJU Int. 93:291–296. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu W, Yin NC, Liu H and Nan KJ: Cav-1
promote lung cancer cell proliferation and invasion through lncRNA
HOTAIR. Gene. 641:335–340. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hada N, Okayasu M, Ito J, Nakayachi M,
Hayashida C, Kaneda T, Uchida N, Muramatsu T, Koike C, Masuhara M,
et al: Receptor activator of NF-κB ligand-dependent expression of
caveolin-1 in osteoclast precursors, and high dependency of
osteoclastogenesis on exogenous lipoprotein. Bone. 50:226–236.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Song N, Liu S, Zhang J, Liu J, Xu L, Liu Y
and Qu X: Cetuximab-induced MET activation acts as a novel
resistance mechanism in colon cancer cells. Int J Mol Sci.
15:5838–5851. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Washington K: 7th edition of the AJCC
cancer staging manual: Stomach. Ann Surg Oncol. 17:3077–3079. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang L, Teng Y, Fan Y, Wang Y, Li W, Shi
J, Ma Y, Li C, Shi X, Qu X and Liu Y: The E3 ubiquitin ligase Cbl-b
improves the prognosis of RANK positive breast cancer patients by
inhibiting RANKL-induced cell migration and metastasis. Oncotarget.
6:22918–22933. 2015.PubMed/NCBI
|
|
27
|
Darnay BG, Ni J, Moore PA and Aggarwal BB:
Activation of NF-kappaB by RANK requires tumor necrosis factor
receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase.
Identification of a novel TRAF6 interaction motif. J Biol Chem.
274:7724–7731. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee SY, Reichlin A, Santana A, Sokol KA,
Nussenzweig MC and Choi Y: TRAF2 is essential for JNK but not
NF-kappaB activation and regulates lymphocyte proliferation and
survival. Immunity. 7:703–713. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen T and Feng X: Cell-based assay
strategy for identification of motif-specific RANK signaling
pathway inhibitors. Assay Drug Dev Technol. 4:473–482. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang L, Teng Y, Zhang Y, Liu J, Xu L, Qu
J, Hou K, Yang X, Liu Y and Qu Y: C-Src-mediated RANKL-induced
breast cancer cell migration by activation of the ERK and Akt
pathway. Oncol Lett. 3:395–400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nakamura ES, Koizumi K, Kobayashi M,
Saitoh Y, Arita Y, Nakayama T, Sakurai H, Yoshie O and Saiki I:
RANKL-induced CCL22/macrophage-derived chemokine produced from
osteoclasts potentially promotes the bone metastasis of lung cancer
expressing its receptor CCR4. Clin Exp Metastasis. 23:9–18. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mori K, Le Goff B, Charrier C, Battaglia
S, Heymann D and Redini F: DU145 human prostate cancer cells
express functional receptor activator of NFkappaB: New insights in
the prostate cancer bone metastasis process. Bone. 40:981–990.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Baillat G, Siret C, Delamarre E and Luis
J: Early adhesion induces interaction of FAK and Fyn in lipid
domains and activates raft-dependent Akt signaling in SW480 colon
cancer cells. Biochim Biophys Acta. 1783:2323–2331. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Babina I, McSherry EA, Donatello S, Hill
AD and Hopkins AM: A novel mechanism of regulating breast cancer
cell migration via palmitoylation-dependent alterations in the
lipid raft affiliation of CD44. Breast Cancer Res. 16:R192014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chinni SR, Sivalogan S, Dong Z, Filho JC,
Deng X, Bonfil RD and Cher ML: CXCL12/CXCR4 signaling activates
Akt-1 and MMP-9 expression in prostate cancer cells: The role of
bone microenvironment-associated CXCL12. Prostate. 66:32–48. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yamaguchi H, Takeo Y, Yoshida S, Kouchi Z,
Nakamura Y and Fukami K: Lipid rafts and caveolin-1 are required
for invadopodia formation and extracellular matrix degradation by
human breast cancer cells. Cancer Res. 69:8594–8602. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chinni SR, Yamamoto H, Dong Z, Sabbota A,
Bonfil RD and Cher ML: CXCL12/CXCR4 transactivates HER2 in lipid
rafts of prostate cancer cells and promotes growth of metastatic
deposits in bone. Mol Cancer Res. 6:446–457. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Patra SK: Dissecting lipid raft
facilitated cell signaling pathways in cancer. Biochim Biophys
Acta. 1785:182–206. 2008.PubMed/NCBI
|
|
39
|
Zhang J, Wang S, Jiang B, Huang L, Ji Z,
Li X, Zhou H, Han A, Chen A, Wu Y, et al: c-Src phosphorylation and
activation of hexokinase promotes tumorigenesis and metastasis. Nat
Commun. 8:137322017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Summy JM and Gallick GE: Src family
kinases in tumor progression and metastasis. Cancer Metastasis Rev.
22:337–358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Irby RB and Yeatman TJ: Role of Src
expression and activation in human cancer. Oncogene. 19:5636–5642.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mitra SK and Schlaepfer DD:
Integrin-regulated FAK-Src signaling in normal and cancer cells.
Curr Opin Cell Biol. 18:516–523. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Buczynski G and Potter RL: Nucleoside
diphosphate kinase from Xenopus oocytes; partial purification and
characterization. Biochim Biophys Acta. 1041:296–304. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Thomas SM and Brugge JS: Cellular
functions regulated by Src family kinases. Annu Rev Cell Dev Biol.
13:513–609. 1997. View Article : Google Scholar : PubMed/NCBI
|
